S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Alibaba Unveils Its Spin-Off Plans
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
The Most Upgraded Stocks From The Q1 Earnings Season
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can the Dow's 2023 Runaway Winners Keep Running?
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Can These Two Crypto Stocks Stage a Comeback?
Advance Auto Parts Backfires: Is This A Warning For The S&P 500?
NASDAQ:BNTX

BioNTech (BNTX) Stock Forecast, Price & News

$105.08
+0.73 (+0.70%)
(As of 05/31/2023 ET)
Compare
Today's Range
$103.84
▼
$106.10
50-Day Range
$102.58
▼
$129.66
52-Week Range
$100.08
▼
$188.99
Volume
393,472 shs
Average Volume
702,923 shs
Market Capitalization
$25.56 billion
P/E Ratio
4.04
Dividend Yield
N/A
Price Target
$172.20
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BioNTech MarketRank™ Forecast

Analyst Rating
Hold
2.46 Rating Score
Upside/​Downside
63.9% Upside
$172.20 Price Target
Short Interest
Healthy
0.83% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.37mentions of BioNTech in the last 14 days
Based on 19 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-51.29%
From $5.42 to $2.64 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.38 out of 5 stars

Medical Sector

131st out of 1,006 stocks

Biological Products, Except Diagnostic Industry

19th out of 167 stocks

See Top Rated MarketRank™ Stocks Here

BNTX stock logo

About BioNTech (NASDAQ:BNTX) Stock

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; Regeneron Pharmaceuticals, Inc. and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Stock News Headlines

May 30, 2023 | americanbankingnews.com
BioNTech SE (NASDAQ:BNTX) Receives $172.20 Consensus Price Target from Analysts
May 28, 2023 | fool.com
BioNTech Se (NASDAQ: BNTX)
June 1, 2023 | Legacy Research (Affiliate) (Ad)
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
May 26, 2023 | msn.com
EU negotiates extended COVID-19 vaccine contract with Pfizer-BioNTech
May 26, 2023 | msn.com
Pfizer and BioNTech reach a deal with EU to change covid vaccine contract
May 26, 2023 | msn.com
Pfizer, BioNTech agree to revise EU COVID vaccine deal
May 26, 2023 | msn.com
Amended European Deal For BioNTech-Pfizer's Covid-19 Vaccines Allows Reduced Purchases
May 26, 2023 | americanbankingnews.com
Q2 2023 Earnings Forecast for BioNTech SE Issued By HC Wainwright (NASDAQ:BNTX)
June 1, 2023 | Legacy Research (Affiliate) (Ad)
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin
$100 is all you need… Former Goldman Sachs managing director Dr. Nomi Prins has identified an investment she’s calling ‘the world’s hardest asset’ – and she’s recommending it to friends, family, and followers.
May 25, 2023 | finance.yahoo.com
BioNTech's Ready-to-Use Single Dose Vaccine, the Perfect Counterattack to China's Rising XBB1.5 Cases
May 25, 2023 | seekingalpha.com
BioNTech readying next COVID shot in line WHO guidance
May 25, 2023 | msn.com
BioNTech readying next COVID shot in line with WHO guidance
May 25, 2023 | americanbankingnews.com
BioNTech (NASDAQ:BNTX) Price Target Cut to $198.00
May 22, 2023 | seekingalpha.com
BioNTech: Able To Tap Into High Medical Need PD-L1 Refractory NSCLC Market
May 20, 2023 | americanbankingnews.com
Deutsche Bank Aktiengesellschaft Trims BioNTech (NASDAQ:BNTX) Target Price to $120.00
May 19, 2023 | msn.com
CureVac’s Lawsuit against Pfizer, BioNTech Picks Up Steam
May 19, 2023 | finance.yahoo.com
Are Options Traders Betting on a Big Move in BioNTech (BNTX) Stock?
May 19, 2023 | msn.com
CureVac accelerates COVID patent dispute with Pfizer/BioNTech as court grants motion
May 18, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG) and BioNTech SE (BNTX)
May 18, 2023 | entrepreneur.com
3 Buy Worthy Biotech Stocks for May
May 17, 2023 | markets.businessinsider.com
Analysts Offer Insights on Healthcare Companies: Galapagos (GLPG), BioNTech SE (BNTX) and Olink Holding (OLK)
May 17, 2023 | markets.businessinsider.com
What To Know About Redburn Partners's Upgrade of BioNTech
May 17, 2023 | americanbankingnews.com
Redburn Partners Upgrades BioNTech (NASDAQ:BNTX) to Buy
May 12, 2023 | seekingalpha.com
BioNTech: Hold Out For More Data (Rating Downgrade)
May 11, 2023 | americanbankingnews.com
BioNTech (NASDAQ:BNTX) Hits New 52-Week Low at $103.70
May 10, 2023 | reuters.com
BioNTech, Roche's experimental pancreatic cancer treatment wins Nature plaudit
May 10, 2023 | markets.businessinsider.com
BioNTech SE (BNTX) Receives a Buy from Berenberg Bank
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

BNTX Company Calendar

Last Earnings
5/08/2023
Today
5/31/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BNTX
CUSIP
N/A
CIK
1776985
Web
www.biontech.de
Phone
49-61-31908-40
Fax
49-6131-908-4390
Employees
4,530
Year Founded
2008

Price Target and Rating

Average Stock Price Forecast
$172.20
High Stock Price Forecast
$260.00
Low Stock Price Forecast
$120.00
Forecasted Upside/Downside
+63.9%
Consensus Rating
Hold
Rating Score (0-4)
2.46
Research Coverage
13 Analysts

Profitability

EPS (Most Recent Fiscal Year)
$26.01
Trailing P/E Ratio
4.04
Forward P/E Ratio
19.39
P/E Growth
N/A
Net Income
$9.94 billion
Net Margins
51.03%
Pretax Margin
69.48%
Return on Equity
32.52%
Return on Assets
27.56%

Debt

Debt-to-Equity Ratio
0.01
Current Ratio
12.95
Quick Ratio
12.68

Sales & Book Value

Annual Sales
$18.24 billion
Price / Sales
1.40
Cash Flow
$41.37 per share
Price / Cash Flow
2.54
Book Value
$89.44 per share
Price / Book
1.17

Miscellaneous

Outstanding Shares
243,210,000
Free Float
196,518,000
Market Cap
$25.56 billion
Optionable
Not Optionable
Beta
0.21

Social Links


Key Executives

  • Prof. Ugur Sahin M.D. (Age 57)
    Co-Founder, CEO & Chair of the Management Board
    Comp: $724.29k
  • Dr. Ozlem Tureci M.D. (Age 55)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $717.89k
  • Prof. Christoph Hubert Huber M.D. (Age 78)
    Ph.D., Co-Founder & Member of Supervisory Board
    Comp: $62.94k
  • Mr. Jens H. Holstein (Age 59)
    CFO & Member of Management Board
    Comp: $868.29k
  • Dr. Sierk Poetting Ph.D. (Age 49)
    MD, COO & Member of Management Board
    Comp: $760.56k
  • Mr. Ryan Richardson (Age 43)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $657.09k
  • Mr. Sean Marett (Age 57)
    Chief Bus. Officer, Chief Commercial Officer & Member of Management Board
    Comp: $821.36k
  • Sylke Maas Ph.D.
    VP of Investor Relations and Bus. Strategy
  • Dr. James Timothy Patrick Ryan Ph.D.
    Sr. VP & Gen. Counsel
  • Michael Boehler
    MD & Head of Global External Communications

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













BNTX Stock - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 6 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BNTX shares.
View BNTX analyst ratings or view top-rated stocks.

What is BioNTech's stock price forecast for 2023?

12 brokerages have issued 12-month price targets for BioNTech's shares. Their BNTX share price forecasts range from $120.00 to $260.00. On average, they expect the company's share price to reach $175.62 in the next year. This suggests a possible upside of 67.1% from the stock's current price.
View analysts price targets for BNTX or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2023?

BioNTech's stock was trading at $150.22 at the start of the year. Since then, BNTX shares have decreased by 30.0% and is now trading at $105.08.
View the best growth stocks for 2023 here.

Are investors shorting BioNTech?

BioNTech saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 2,020,000 shares, an increase of 5.2% from the April 30th total of 1,920,000 shares. Based on an average trading volume of 699,600 shares, the days-to-cover ratio is currently 2.9 days.
View BioNTech's Short Interest.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our BNTX earnings forecast.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) released its quarterly earnings data on Monday, May, 8th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $0.18 by $1.87. The firm earned $1.28 billion during the quarter, compared to analysts' expectations of $1.09 billion. BioNTech had a net margin of 51.03% and a trailing twelve-month return on equity of 32.52%. BioNTech's revenue for the quarter was down 80.0% compared to the same quarter last year. During the same quarter last year, the company earned $15.98 EPS.

What ETFs hold BioNTech's stock?

ETFs with the largest weight of BioNTech (NASDAQ:BNTX) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), VanEck Biotech ETF (BBH), First Trust NYSE Arca Biotechnology Index Fund (FBT), Franklin Genomic Advancements ETF (HELX) and Loncar Cancer Immunotherapy ETF (CNCR).

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

(BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

What is BioNTech's stock symbol?

BioNTech trades on the NASDAQ under the ticker symbol "BNTX."

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (3.10%), Flossbach Von Storch AG (1.41%), Artisan Partners Limited Partnership (1.07%), BlackRock Inc. (0.79%), Envestnet Asset Management Inc. (0.40%) and Twin Tree Management LP (0.00%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioNTech's stock price today?

One share of BNTX stock can currently be purchased for approximately $105.08.

How much money does BioNTech make?

BioNTech (NASDAQ:BNTX) has a market capitalization of $25.56 billion and generates $18.24 billion in revenue each year. The company earns $9.94 billion in net income (profit) each year or $26.01 on an earnings per share basis.

How many employees does BioNTech have?

The company employs 4,530 workers across the globe.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
How can I contact BioNTech?

BioNTech's mailing address is AN DER GOLDGRUBE 12, MAINZ 2M, 55131. The official website for the company is www.biontech.de. The company can be reached via phone at 49-61-31908-40, via email at investors@biontech.de, or via fax at 49-6131-908-4390.

This page (NASDAQ:BNTX) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -